News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Furiex Pharmaceuticals, Inc. (FURX) Study Results to be Presented at the American College of Gastroenterology 2011 Annual Scientific Meeting


10/31/2011 9:31:11 AM

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), a drug development collaboration company, announced its late-breaking abstract describing results from the Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, its investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome, was accepted for presentation at the upcoming American College of Gastroenterology Annual Scientific Meeting in Washington, DC. Dr. Charles Randall, clinical professor of medicine at the University of Texas Health Science Center of San Antonio and an investigator in this recently completed trial, will present the results at the Plenary Session 2, on November 1, 2011 at the Gaylord National Hotel and Convention Center in Washington, DC.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES